Review: Side effects of approved molecular targeted therapies in solid cancers

Oncologist

Volumn 12, Issue 12, 2007, Pages 1443-1455

  Widakowich, Christian ^a,b   De Castro Jr , Gilberto ^c   De Azambuja, Evandro ^a,b   Dinh, Phuong ^a   Awada, Ahmad ^a,b  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anti EGFR agents; Anti HER 2 agents; Anti VEGFR agents; Targeted therapy; Toxicity

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SORAFENIB; SUNITINIB; THYROTROPIN; TRASTUZUMAB; TRIACYLGLYCEROL LIPASE; UNINDEXED DRUG; VASCULOTROPIN;

ABDOMINAL PAIN; ACNE; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; APHTHOUS ULCER; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; BULLOUS SKIN DISEASE; CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; CELL FUNCTION; CHILL; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTINUOUS INFUSION; DEPIGMENTATION; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EDEMA; EPISTAXIS; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLICULITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HAIR DISEASE; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HEADACHE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERCOAGULABILITY; HYPERKERATOSIS; HYPERTENSION; HYPERTRICHOSIS; HYPOTHYROIDISM; INJECTION SITE PAIN; INTERSTITIAL LUNG DISEASE; KIDNEY CARCINOMA; LUNG CANCER; LUNG HEMORRHAGE; LUNG TOXICITY; MONOTHERAPY; MOUTH PAIN; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NAIL DISEASE; NAUSEA; NEUTROPENIA; ORAL BLEEDING; PARONYCHIA; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PERIORBITAL EDEMA; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROTEINURIA; PROTHROMBIN TIME; RASH; REVIEW; SEIZURE; SIDE EFFECT; SKIN BRUISING; SKIN EXFOLIATION; SKIN PRURITUS; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; THROMBOSIS; THYROIDITIS; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TRICHOMEGALY; VAGINAL DRYNESS; VASOSPASM; VENOUS THROMBOEMBOLISM; VISUAL IMPAIRMENT; VOMITING; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 38049025794     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-12-1443     Document Type: Review

References (114)

1. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nature 2006;6:714-727.
2. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-297.
3. Chen WS, Lazar CS, Poenie M et al. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature 1987;328:820-823.
4. Jost M, Kari C, Rodeck U. The EGF receptor: An essential regulator of multiple epidermal functions. Eur J Dermatol 2000;10:505-510.
5. Lynch TJ Jr, Kim ES, Eaby B et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. The Oncologist 2007;12:610-621.
6. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-497.
7. Huang S, Armstrong EA, Benavente S et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004;64:5355-5362.
8. Xia W, Gerard CM, Liu L et al. Combining lapatininb (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005;24:6213-6221.
9. Riese DJ 2nd, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998;20:41-48.
10. Strachan L, Murison JG, Prestidge RL et al. Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J Biol Chem 2001;276:18265-18271.
11. Yano S, Kondo K, Yamaguchi M et al. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 2003;23:3639-3650.
12. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer 2002;94:1593-1611.
13. Castillo L, Etienne-Grimaldi MC, Fischel JL et al. Pharmacological background of EGFR targeting. Ann Oncol 2004;15:1007-1012.
14. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
15. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 2002;20:2240-2250.
16. Soulieres D, Senzer NN, Vokes EE et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.
17. Busam KJ, Capodieci P, Motzer R et al. Cutaneous side-effects in patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-1176.
18. Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002;138:129-131.
19. Van Doorn R, Kirtschig G, Scheffer E et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002;147:598-601.
20. Jacot W, Bessis D, Jorda E et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004;151:238-241.
21. Lee MW, Seo CW, Kim SW et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004;84:23-26.
22. Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-3279.
23. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-914.
24. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-4302.
25. Fernandez-Galar M, Espana A, Lopez-Picazo JM. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clin Exp Dermatol 2004;29:138-140.
26. Alexandrescu DT, Vaillant JG, Dasanu CA. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol 2007;32:71-74.
27. Jatoi A, Rowland K, Sloan JA et al. Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash?Aphase III trial from the North Central Cancer Treatment Group (N03CB). J Clin Oncol 2007;25(18 suppl):Abstract LBA9006.
28. Agero AL, Dusza SW, Benvenuto-Andrade C et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. JAm Acad Dermatol 2006;55:657-670.
29. Kari C, Chan TO, Rocha de Quadros M et al. Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage. Cancer Res 2003;63:1-5.
30. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-812.
31. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park) 2003;17(suppl 12):23-28.
32. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-1433.
33. Playford RJ, Ghosh S, Mahmood A. Growth factors and trefoil peptides in gastrointestinal health and disease. Curr Opin Pharmacol 2004;4:567-571.
34. Matsuura M, Okazaki K, Nishio A et al. Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis. Gastroenterology 2005;128:975-986.
35. Threadgill DW, Dlugosz AA, Hansen LA et al. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 1995;269:230-234.
36. Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004;22:3003-3015.
37. Robert F, Blumenschein G, Herbst RS et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 2005;23:9089-9096.
38. Vincenzi B, Santini D, Rabitti C et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: A single centre phase II trial. Br J Cancer 2006;94:792-797.
39. Cappuzzo F, Bartolini S, Ceresoli GL et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer 2004;90:82-86.
40. Veronese ML, Sun W, Giantonio B et al. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br J Cancer 2005;92:1846-1849.
41. Kawamura M, Eguchi K, Izumi Y et al. Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer. Cancer Chemother Pharmacol 2007;60:495-501.
42. Astra Zeneca. Expert Committee Meeting Report: Final Report on Interstitial Lung Disease (ILD) Related to Gefitinib (Iressa Tablet 250) by Iressa Expert Committee. Wilmington, DE: Astra Zeneca, March 26, 2003.
43. Takeyama K, Dabbagh K, Lee HM et al. Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci U S A 1999;96:3081-3086.
44. Inoue A, Saijo Y, Maemondo M et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-139.
45. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
46. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369:29-36.
47. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
48. Slamon D, Eiermann W, Robert N et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients. Paper presented at San Antonio Breast Cancer Symposium; San Antonio, TX; December 14-17, 2006.
49. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
50. Carter P, Presta L, Gorman CM et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-4289.
51. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-1221.
52. Chia S, Clemons M, Martin LA et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multi-centre phase II trial. J Clin Oncol 2006;24:2773-2778.
53. Kim E, Gaiotti DA, Volm MD et al. Reversible cardiotoxicity from pegylated liposomal doxorubicin plus trastuzumab (Herceptin): Results from 2 prospective studies. Breast Cancer Res Treat 2004;88:5058a.
54. Wolff AC, Wang M, Sparano JA et al. Cardiac safety and clinical activity of pegylated liposomal doxorubicin and docetaxel with and without trastuzumab as 1st line chemotherapy in HER2 positive and HER-2 negative metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. Breast Cancer Res Treat 2004;88:3040a.
55. Theodoulu M, Campos SM, Batist G et al. TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): Final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 2002;21:55a.
56. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-7826.
57. Garratt AN, Özcelik C, Birchmeier C. ErbB2 pathways in heart and neural diseases. Trends Cardiovasc Med 2003;13:80-86.
58. Özcelik C, Erdmann B, Pilz B et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002;99:8880-8885.
59. Zhao YY, Sawyer DR, Baliga RR et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998;273:10261-10269.
60. Crone SA, Zhao YY, Fan L et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-465.
61. Behr TM, Behe M, Wormann B. Trastuzumab and breast cancer. N Engl J Med 2001;345:995-996.
62. Uray IP, Connelly JH, Thomazy V et al. Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. J Heart Lung Transplant 2002;21:771-782.
63. Carrasco Guerra HA, Palacios-Pru E, Dagert de Scorza C et al. Clinical, histochemical, and ultrastructural correlation in septal endomyocardial biopsies from chronic chagasic patients: Detection of early myocardial damage. Am Heart J 1987;113:716-724.
64. Schaper J, Froede R, Hein S et al. Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation 1991;83:504-514.
65. Xia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-6263.
66. Moy B, Goss P. Lapatinib: Current status and future directions in breast cancer. The Oncologist 2006;11:1047-1057.
67. Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib. The Oncologist 2004;9(suppl 3):10-15.
68. Versola M, Burris H, Jones S et al. Clinical activity of GW572016 in EGF10003 in patients with solid tumors. J Clin Oncol 2004;22(14 suppl):3047a.
69. Jones SF, Hainsworth JD, Spigel DR et al. A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009). J Clin Oncol 2004;22(14 suppl):2083a.
70. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006:355;2733-2743.
71. Sweetman R, Lacouture ME, Koehler M et al. Skin events among 1,126 patients treated with lapatinib, an oral dual ErbB1/2 tyrosine kinase inhibitor. J Clin Oncol 2007;25(18 suppl):9102a.
72. Perez EA, Byrne JA, Hammond IW et al. Results of an analysis of cardiac function in 3558 patients treated with lapatinib. 2006 Meeting of the European Society of Medical Oncology, Istanbul, Turkey; September 29-October 3, 2006.
73. Nakamura T, Matsumoto K. Angiogenesis inhibitors: From laboratory to clinical application. Biochem Biophys Res Commun 2005;333:289-291.
74. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985.
75. Leung DW, Cachianes G, Kuang WJ et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
76. Shing Y, Folkman J, Sullivan R et al. Heparin affinity: Purification of a tumor-derived capillary endothelial cell growth factor. Science 1984;223:1296-1299.
77. Burgess WH, Mehlman T, Marshak DR et al. Structural evidence that endothelial cell growth factor β is the precursor of both endothelial cell growth factor α and acidic fibroblast growth factor. Proc Natl Acad Sci U S A 1986;83:7216-7220.
78. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-442.
79. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
80. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003;21:3542.
81. Caine GJ, Stonelake PS, Lip GY et al. The hypercoagulable state of malignancy: Pathogenesis and current debate. Neoplasia 2002;4:465-473.
82. Haroon Z, Amin K, Saito W et al. SU5416 delays wound healing through inhibition of TGF-beta 1 activation. Cancer Biol Ther 2002;1:121-126.
83. Kabbinavar F. In reply. J Clin Oncol 2003;21:3543.
84. Kuenen BC, Rosen L, Smit EF et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002;20:1657-1667.
85. Saltz LB, Douillard JY, Pirotta N et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: A new survival standard. The Oncologist 2001;6:81-91.
86. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
87. Struijker Boudier HA, le Noble JL, Messing MW et al. The microcirculation and hypertension. J Hypertens Suppl 1992;10:S147-S156.
88. Greene AS. Microvascular Regulation and Dysregulation. Hypertension Primer, Third Edition. Philadelphia: Lippincott Williams and Wilkins, 2003:193-201.
89. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006;20:1363-1369.
90. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004;7:193-201.
91. Hood JD, Meininger CJ, Ziche M et al. VEGF upregulates eNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998;274:H1054-H1058.
92. Henry TD, Annex BH, McKendall GR et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359-1365.
93. Hinchey J, Chaves C, Appignani B et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500.
94. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:980-982.
95. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:980-982.
96. Alavi A, Hood JD, Frausto R et al. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003;301:94-96.
97. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10:6388S-6392S.
98. Ratain MJ, Flaherty KT, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
99. Govindarajan R, Adusumilli J, Baxter DL et al. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006;24:e48.
100. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
101. Moore M, Hirte HW, Siu L et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-1694.
102. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
103. Platts MM, Greaves MS. Splinter haemorrhages. Br Med J 1958;2:143-144.
104. Mujic F, Lloyd M, Cuadrado MJ et al. Prevalence and clinical significance of subungual splinter haemorrhages in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1995;13:327-331.
105. Quenneville JG, Gossard D. Subungueal-splinter hemorrhage an early sign of thromboangiitis obliterans. Angiology 1981;32:424-432.
106. O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-3605.
107. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
108. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-2524.
109. Demetri GD, Van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-1338.
110. Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660-664.
111. Robert C, Spatz A, Faivre S et al. Tyrosine kinase inhibition and grey hair. Lancet 2003;361:1056.
112. Botchkareva NV, Khlgatian M, Longley BJ et al. SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J 2001;15:645-658.
113. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247.
114. Foon KA, Yang XD, Weiner LM et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004;58:984-990.